Plasma lipidomic signatures of dementia with Lewy bodies revealed by machine learning, and compared to Alzheimer's disease
Authors:
Open Access
- 15 October 2024
- journal article
- research article
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 16 (1) , 1-14
Abstract
Dementia with Lewy Bodies (DLB) is a complex neurodegenerative disorder that often overlaps clinically with Alzheimer’s disease (AD), presenting challenges in accurate diagnosis and underscoring the need for novel biomarkers. Lipidomic emerges as a promising avenue for uncovering disease-specific metabolic alterations and potential biomarkers, particularly as the lipidomics landscape of DLB has not been previously explored. We aim to identify potential diagnostic biomarkers and elucidate the disease's pathophysiological mechanisms. This study conducted a lipidomic analysis of plasma samples from patients with DLB, AD, and healthy controls (HCs) at Xuanwu Hospital. Untargeted plasma lipidomic profiling was conducted via liquid chromatography coupled with mass spectrometry. Machine learning methods were employed to discern lipidomic signatures specific to DLB and to differentiate it from AD. The study enrolled 159 participants, including 57 with AD, 48 with DLB, and 54 HCs. Significant differences in lipid profiles were observed between the DLB and HC groups, particularly in the classes of sphingolipids and phospholipids. A total of 55 differentially expressed lipid species were identified between DLB and HCs, and 17 between DLB and AD. Correlations were observed linking these lipidomic profiles to clinical parameters like Unified Parkinson’s Disease Rating Scale III (UPDRS III) and cognitive scores. Machine learning models demonstrated to be highly effective in distinguishing DLB from both HCs and AD, achieving substantial accuracy through the utilization of specific lipidomic signatures. These include PC(15:0_18:2), PC(15:0_20:5), and SPH(d16:0) for differentiation between DLB and HCs; and a panel includes 13 lipid molecules: four PCs, two PEs, three SPHs, two Cers, and two Hex1Cers for distinguishing DLB from AD. This study presents a novel and comprehensive lipidomic profile of DLB, distinguishing it from AD and HCs. Predominantly, sphingolipids (e.g., ceramides and SPHs) and phospholipids (e.g., PE and PC) were the most dysregulated lipids in relation to DLB patients. The lipidomics panels identified through machine learning may serve as effective plasma biomarkers for diagnosing DLB and differentiating it from AD dementia.Keywords
Funding Information
- National Key Research and Development Program of China (2020YFC2003100, 2020YFC2003103)
This publication has 61 references indexed in Scilit:
- Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD)Movement Disorders, 2021
- Vesicle trafficking and lipid metabolism in synucleinopathyActa Neuropathologica, 2020
- High‐resolution metabolomic profiling of Alzheimer’s disease in plasmaAnnals of Clinical and Translational Neurology, 2019
- Dioleoyl‐phosphatidic acid selectively binds to α‐synuclein and strongly induces its aggregationFEBS Letters, 2017
- Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's diseaseMovement Disorders, 2013
- Glucocerebrosidase deficiency in substantia nigra of parkinson disease brainsAnnals of Neurology, 2012
- Alterations of the Sphingolipid Pathway in Alzheimer’s Disease: New Biomarkers and Treatment Targets?NeuroMolecular Medicine, 2010
- Gene Expression Alterations in the Sphingolipid Metabolism Pathways during Progression of Dementia and Alzheimer’s Disease: A Shift Toward Ceramide Accumulation at the Earliest Recognizable Stages of Alzheimer’s Disease?Neurochemical Research, 2007
- Generation and metabolism of bioactive sphingosine‐1‐phosphateJournal of Cellular Biochemistry, 2004
- PC and PE synthesis: Mixed micellar analysis of the cholinephosphotransferase and ethanolaminephosphotransferase activities of human choline/ethanolamine phosphotransferase 1 (CEPT1)Lipids, 2002